At ASM Microbe 2025, a Puerto Rico study linked increased fungal spore concentrations to rises in viral respiratory infections, suggesting potential early warning utility.
At ASM Microbe 2025, a cross-sectional study highlighted Burkholderia cepacia dominance, widespread antibiotic resistance, and key risk factors, including invasive device use and patient demographics.
New modeling estimates up to 360,000 symptomatic cases annually, 10 to 18 times higher than reported, with CDC experts calling for expanded testing, reporting, and clinical awareness.